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Abstract
Background Individuals with heterozygous familial hyper-
cholesterolemia (heFH) have higher levels of low-density
lipoprotein cholesterol (LDL-C) and are predisposed to pre-
mature cardiovascular disease. Alirocumab is a fully-human,
monoclonal antibody targeted to proprotein convertase
subtilisin/kexin type 9 currently in Phase 3 development for
the treatment of hypercholesterolemia. Described here are
three ODYSSEY Phase 3 trials, FH I (NCT01623115), FH
II (NCT01709500) and HIGH FH (patients with heFH and
LDL-C levels ≥160 mg/dL) (NCT01617655), in which
alirocumab is further evaluated in the heFH population.
Methods Multicenter, multinational, randomized, double-
blind, placebo-controlled studies have been designed to eval-
uate efficacy and safety of alirocumab in more than 800
patients with heFH who are not adequately controlled with a
maximally-tolerated stable daily dose of statin for ≥4 weeks
prior to the screening visit, with or without other lipid-
lowering therapy. Patients are randomized (2:1) to receive
alirocumab or placebo via a 1-mL subcutaneous auto-
injection every 2 weeks (Q2W) for 78 weeks. In studies FH
I and II, if their Week 8 LDL-C level is ≥70 mg/dL, patients
will undergo a dose uptitration from 75 to 150 mg alirocumab
Q2W at Week 12. In HIGH FH, patients will receive
alirocumab 150 mg Q2W throughout the entire treatment
period. The primary efficacy endpoint in all three studies is
the percent change in calculated LDL-C from baseline to
Week 24.
Conclusions The ODYSSEY FH studies are three Phase 3
studies aiming to further evaluate the efficacy and long-term
safety of alirocumab as an effective therapeutic option for
patients with heFH.
Keywords Alirocumab . Heterozygous familial
hypercholesterolemia . LDL-C . PCSK9
Introduction
Heterozygous familial hypercholesterolemia (heFH) is a he-
reditary lipid metabolism disorder that predisposes affected
individuals to cardiovascular (CV) disease [1]. Patients with
heFH typically have very high low-density lipoprotein cho-
lesterol (LDL-C) levels—often >190 mg/dL at the time of
diagnosis—that are associated with high risk for premature
CV disease [2, 3]. However, a recent consensus statement
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highlights that in most countries less than 1 % of patients with
heFH are, in fact, diagnosed [4].
Findings from observational studies have shown that the
risk of coronary heart disease (CHD) is reduced in heFH
patients receiving statin therapy [5–7]; however, even with
this treatment, the risk of CHD is still greater in heFH patients
than in the general population [5]. Despite the availability of
lipid-lowering therapy (LLT), approximately 80 % of patients
with heFH do not reach the recommended levels of LDL-C
[8–12]. Given the increased CV risk in the heFH population,
there is a need to provide patients with additional and more
intensive lipid-lowering therapy [4, 13].
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a
therapeutic target currently under investigation, binds to LDL-
C receptors, resulting in their degradation so that fewer recep-
tors are available on liver cells to remove excess LDL-C from
the plasma [14–17].
PCSK9 inhibition has the potential to provide a comple-
mentary mechanism to other LLTs to significantly reduce
LDL-C beyond the efficacy of statins [15, 17–25].
Alirocumab (formerly REGN727/SAR236553; Sanofi-
Regeneron) is a fully human, monoclonal antibody targeted
to PCSK9 currently in Phase 3 development for the treatment
of hypercholesterolemia.
In Phase 2 trials, alirocumab demonstrated significant re-
ductions in LDL-C levels in patients receiving concomitant
statin or statin plus ezetimibe therapy [NCT01288443;
NCT01266876; NCT01288469; 21, 23, 24]. In these studies,
alirocumab significantly (p<0.001) reduced mean LDL-C
levels by up to 72.4 %, and also showed favorable trends in
other atherogenic lipid parameters including lipoprotein(a)
[Lp(a)], triglycerides, non-high-density lipoprotein cholester-
ol (non-HDL-C), apolipoprotein (Apo) B, and anti-atherogenic
fractions HDL-C and Apo A1. Specifically, a Phase 2 trial
demonstrated that alirocumab reduced mean LDL-C levels by
up to 67.9 % (p<0.0001) in patients with heFH [24]. No dose-
limiting adverse events (AEs) were identified in the Phase 2
studies [21, 23, 24], with the most common treatment-
emergent AE (TEAE) in patients receiving alirocumab being
mild injection site reaction. Five serious AEs (SAEs) occurred
in four patients (1.5 %) who received alirocumab and two
SAEs occurred in two patients (2.6 %) who received placebo.
The ODYSSEY Phase 3 alirocumab clinical trial program
is designed to further assess the efficacy and safety of
alirocumab in a range of clinical settings. The trials within
the program evaluate a treat-to-goal approach, using a flexible
dosing strategy for individualized therapy based on degree of
LDL-C lowering required to achieve an adequate treatment
response. This approach is designed to address patient popu-
lations unable to achieve desired LDL-C levels with the
current standard of care. The program comprises a total of
14 studies planned to include more than 23,500 patients in
over 2,000 study centers worldwide. Of these studies,
the ODYSSEY program also includes a large cardiovascular
outcomes trial evaluating the long-term impact of alirocumab
and lower levels of LDL-C on the occurrence of cardiovascu-
lar events in 18,000 patients after a recent (<52 weeks) acute
coronary syndrome event, with a randomized treatment period
of 64 months. The aim of the ODYSSEY FH studies is to
assess the efficacy and safety of alirocumab in patients with
heFH who, despite their maximally-tolerated statin dose, with
or without other LLT, continue to have suboptimal LDL-C
levels and require additional pharmacologic management.
Methods
Study Design
All three Phase 3 ODYSSEYFH clinical trials are multicenter,
multinational, randomized, double-blind, placebo-controlled
studies designed to evaluate the efficacy and safety of
alirocumab in patients with heFH not adequately controlled
with their current LLT.
The FH I study (ClinicalTrials.gov identif ier:
NCT01623115) is being conducted at 89 sites across North
America, Europe and South Africa, and has a planned popu-
lation of 471 patients. The FH II study (ClinicalTrials.gov
identifier: NCT01709500) is being conducted at 26 sites
across Europe and has a planned population of 250 patients.
Both the FH I and II studies enroll heFH patients
who have LDL-C levels ≥70 mg/dL at the screening
visit and have a history of documented CVD, or heFH
patients with LDL-C ≥100 mg/dL at the screening visit
without a history of documented CVD (Fig. 1).
The HIGH FH study (ClinicalTrials.gov identifier:
NCT01617655) is being conducted at 33 sites across
North America, Europe and South Africa, and has a
planned population of 105 patients with heFH and LDL-C
levels ≥160 mg/dL at the screening visit (Fig. 1).
The studies are being performed in accordance with the
ethical principles that have their origin in the Declaration of
Helsinki and all applicable amendments laid down by the
World Medical Assemblies and the International Conference
Harmonisation guidelines for Good Clinical Practice.
Institutional review board or independent ethics committee
approval of the protocols and informed consent forms were
obtained from each study site, and written informed consent
was obtained from all patients.
Study Objectives
The primary efficacy objective in all three studies is to dem-
onstrate the reduction of LDL-C by alirocumab, in compari-
son with placebo, as add-on therapy to stable, maximally
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tolerated daily statin therapy, with or without other LLT, after
24 weeks of treatment in patients with heFH. Secondary
objectives common to all three studies include the evaluation
of the effect of alirocumab in comparison with placebo on
LDL-C after 12 weeks of treatment; the effect of alirocumab
on other lipid parameters, e.g., Apo B, non-HDL-C, total
cholesterol, Lp(a), HDL-C, triglycerides and Apo A1 levels;
the long-term effect of alirocumab on LDL-C; the safety and
tolerability of alirocumab; and evaluation of the development
of anti-alirocumab antibodies.
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Inclusion Criteria
The principal inclusion criteria for all three studies are patients
with heFH who are not adequately controlled with a maximally
tolerated stable daily dose of statin for at least 4 weeks prior to
the screening visit, with or without other LLT (Table 1).
The diagnosis of heFH must be made either by genotyping
or clinical criteria. For those patients not genotyped, the
clinical diagnosis may be based on either the Simon Broome
criteria [26], meeting the criteria for definite FH, or the World
Health Organization (WHO)/Dutch Lipid Network criteria
[27] with a score of >8 points.
Exclusion Criteria
The principal exclusion criteria for the FH I and II studies
include patients with different LDL-C thresholds depending
on their cardiovascular risk status: LDL-C <70 mg/dL
(<1.81 mmol/L) in patients with history of documented
CVD and LDL-C <100 mg/dL (<2.59 mmol/L) in patients
without history of documented CVD.
The principal exclusion criterion for the HIGH FH study
includes patients with an LDL-C level of <160 mg/dL
(<4.14 mmol/L) at the screening visit (Table 1). Other key
exclusion criteria common to the three studies are shown in
Table 1.
Study Procedures
The three FH studies consist of three periods: a screening period
of up to 3 weeks, during which the patient or another designated
person is trained to self-inject/inject study medication (1 mL
administered via auto-injector); a 78-week double-blind treat-
ment period; and an 8-week off-treatment follow-up period. It
should be noted that, at the end of the 78-week treatment period
in each study, patients will be offered the possibility to enter an
open-label extension study, in which they will receive
alirocumab. If patients opt out of entering the open-label treat-
ment period, they will enter the 8-week follow-up period.
In FH I, FH II and HIGH FH, all eligible patients are
randomized 2:1 to alirocumab or placebo. Randomization is
stratified according to history of myocardial infarction (MI) or
ischemic stroke for balance across study arms, intensity of
statin treatment (atorvastatin 40 to 80mg daily, or rosuvastatin
20 to 40 mg daily versus simvastatin irrespective of the daily
dose, atorvastatin below 40 mg daily or rosuvastatin below
20 mg daily), and geographic region (where applicable).
At randomization, treatment kit numbers are allocated
using a centralized treatment allocation system, which is either
an interactive voice response system or an interactive web
response system, depending on the site preference. Study
patients, principal investigators and study site personnel re-
main blinded to all randomization assignments throughout the
Table 1 Principal inclusion and exclusion criteria for ODYSSEY FH I, FH II, and HIGH FH
Principal inclusion criteria for all three studies
Patients with heFH who are not adequately controlleda with a maximally-tolerated stable daily dose of statinb for
at least 4 weeks prior to the screening visit, with or without other LLT
Principal exclusion criteria
Not on a stable dose of LLT (including statin) for at least 4 weeks and/or fenofibrate for at least 6 weeks, as applicable,
prior to the screening visit or from screening to randomization
Currently taking a statin that is not simvastatin, atorvastatin or rosuvastatin taken daily at a registered dose
Receiving daily doses above atorvastatin 80 mg, rosuvastatin 40 mg or simvastatin 40 mg (except for patients on
simvastatin 80 mg for more than 1 year, who are eligible)
Use of fibrates, other than fenofibrate, within 6 weeks of the screening visit
Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) at the screening visit
Known history of homozygous FH
FH I and II HIGH FH
History of documented CVD and LDL-C <70 mg/dL (<1.81 mmol/L)
at the screening visit
Without history of documented CVD and LDL-C <100 mg/dL (<2.59 mmol/L)
at the screening visit
LDL-C <160 mg/dL (<4.14 mmol/L) at the screening visit AND
patient only on statin monotherapy without additional LLT
CVD cardiovascular disease, FH familial hypercholesterolemia, heFH heterozygous familial hypercholesterolemia, LDL-C low-density lipoprotein
cholesterol, LLT lipid-lowering therapy, MI myocardial infarction
a FH I and II: not adequately controlled defined as an LDL-C ≥70mg/dL at the screening visit in patients with a history of documented CVDORLDL-C
≥100mg/dL at the screening visit in patients without a history of documented CVD. HIGH FH: not adequately controlled defined as an LDL-C ≥160mg/
dL at the screening visit
bMaximally-tolerated statin dose defined as: the highest tolerable registered dose of daily statin currently administered to the patient, that is rosuvastatin
20 mg or 40 mg daily; atorvastatin 40 mg or 80 mg daily; simvastatin 80 mg daily (if already on this dose for >1 year). Patients who are not able to be on
any of the above statin doses should be treated with the dose of daily atorvastatin, rosuvastatin, or simvastatin which is considered appropriate for the
patient, according to the investigator’s judgment
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study. All lipid and anti-drug antibody results collected after
randomization are masked.
In the three studies, the first auto-injection during the
double-blind treatment period takes place at the site on the
day of randomization (Week 0). Subsequent auto-injections
are done by the patient or another designated person such as a
spouse or relative at a patient-preferred location and occur
every 2 weeks.
In FH I and FH II, patients randomized to alirocumab will
receive a 75 mg 1 mL dose every 2 weeks (Q2W). Patients
randomized to placebo will receive a 1 mL subcutaneous
placebo injection in an identical auto-injector to maintain
blinding. At Week 12, patients randomized to alirocumab
undergo a dose uptitration to 150 mg Q2W, also given as a
1 mL auto-injection, if the Week 8 LDLC level is ≥70 mg/dL
(1.81 mmol/L). The continuation of the 75 mg dose or dose
up-titration to the 150 mg dose will occur in an automated
process without site or patient awareness.
In HIGH FH, at study entry, patients have an LDL-C level
of ≥160 mg/dL (4.14 mmol/L) and they will be randomized to
receive a 150-mg 1 mL dose of alirocumab or placebo-
alirocumab, without the uptitration process, from randomiza-
tion to the end of the 78-week double-blind treatment period.
During the three FH studies, all patients are asked to follow
a stable, National Cholesterol Education Program Adult
Treatment Panel III Therapeutic Lifestyle Changes diet or
equivalent throughout the entire study duration from
screening to completion.
Key Study Endpoints and Assessments
The primary efficacy endpoint in all three studies is the
percent change in calculated LDL-C from baseline to Week
24, using all LDL-C values regardless of adherence to
treatment (intent-to-treat [ITT] approach). Key second-
ary endpoints are summarized in Table 2.
In FH I, II andHIGH FH, LDL-Cwill be calculated using the
Friedewald formula at screening and at all time points during the
double-blind treatment periods. In FH I and II, if triglycerides
exceed 400 mg/dL (4.52 mmol/L) then the central laboratory
will reflexively measure LDL-C (via the beta quantification
method) rather than calculating it. LDL-C will also be measured
(via the beta quantification method) at Week 0 and Week 24.
On-site patient assessments take place at Weeks 0, 12, 24,
36, 52, 64, 78, and 86, the end-of-study visit. All laboratory
tests are performed by the central laboratory.
Safety parameters (AEs [including adjudicated CV events
categorized as CHD death, non-fatal MI, fatal and non-fatal
ischemic stroke, unstable angina requiring hospitalization,
congestive heart failure requiring hospitalization], labora-
tory data [blood biochemistry, hematology and urinaly-
sis], vital signs and electrocardiogram) are assessed
throughout the study.
Statistical Design and Analysis
Sample Size Determination
In each study (FH I, FH II and HIGH FH), a total sample size
of 45 patients (30 in the alirocumab and 15 in the placebo
Table 2 Primary and key secondary endpoints common to FH I, FH II
and HIGH FH
Primary endpoint
% change in calculated LDL-C from baseline to Week 24 in the ITT
population, using all LDL-C values regardless of adherence to
treatment (ITT estimand)
Key secondary endpoints
% change in calculated LDL-C from baseline to Week 24 in the mITT
population, using all LDL-C values during the efficacy treatment
period (on-treatment estimand)
% change in LDL-C from baseline to Week 12 (ITT estimand)
% change in LDL-C from baseline toWeek 12 (on-treatment estimand)
% change in Apo B from baseline to Week 24 (ITT estimand)
% change in Apo B from baseline to Week 24 (on-treatment estimand)
% change in non-HDL-C from baseline to Week 24 (ITT estimand)
% change in non-HDL-C from baseline to Week 24 (on-treatment
estimand)
% change in total cholesterol from baseline toWeek 24 (ITTestimand)
% change in Apo B from baseline to Week 12 (ITT estimand)
% change in non-HDL-C from baseline to Week 12 (ITT estimand)
% change in total cholesterol from baseline toWeek 12 (ITTestimand)
% change in calculated LDL-C from baseline to Week 52 (ITT
estimand)
Proportion of very high CV risk patients reaching calculated LDL-C
<70 mg/dL (1.81 mmol/L) or high CV risk patients reaching
calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 (ITT
estimand)
Proportion of very high CV risk patients reaching calculated LDL-C<
70 mg/dL (1.81 mmol/L) or high CV risk patients reaching
calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 (on-
treatment estimand)
Proportion of patients reaching LDL-C <70 mg/dl (1.81 mmol/L) at
Week 24 (ITT estimand)a
Proportion of patients reaching LDL-C <70 mg/dl (1.81 mmol/L) at
Week 24 (on-treatment estimand)a
% change in Lp(a) from baseline to Week 24 (ITT estimand)
% change in HDL-C from baseline to Week 24 (ITT estimand)
% change in fasting TG from baseline to Week 24 (ITT estimand)
% change in Apo A1 from baseline to Week 24 (ITT estimand)
% change in Lp(a) from baseline to Week 12 (ITT estimand)
% change in HDL-C from baseline to Week 12 (ITT estimand)
% change in fasting TG from baseline to Week 12 (ITT estimand)
% change in Apo A1 from baseline to Week 12 (ITT estimand)
Apo apolipoprotein, FH familial hypercholesterolemia, HDL-C high-den-
sity lipoprotein cholesterol, ITT intent-to-treat, LDL-C low-density lipopro-
tein cholesterol, Lp(a) lipoprotein(a), mITTmodified ITT, TG triglycerides
a Proportion of patients reaching LDL-C <70 mg/dL (ITTand on-treatment
estimand) are the last key secondary endpoints for HIGH FH
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group) will have 95 % power to detect a difference in mean
percent change in LDL-C of 30 % with a 0.05 two-sided
significance level, assuming a common standard deviation of
25 % and all these 45 patients having an evaluable primary
endpoint.
However, to meet regulatory requirements across the pro-
gram, sample sizes were increased to assess the safety of
alirocumab appropriately. Therefore, the final total sample
sizes were increased and rounded to 471 in FH I, 250 in FH
II and 105 in HIGH FH.
Analysis Populations for Each of the FH Studies
Primary Analysis The primary analysis population will be the
ITT population and will comprise all randomized patients with
at least one baseline calculated LDL-C value available and at
least one calculated LDL-C value available between Weeks 4
and 24 (regardless of treatment adherence). The percent change
from baseline in LDL-C at Week 24 will be analyzed using a
mixed effect model with repeated measures (MMRM) ap-
proach. All available post-baseline data from Week 4 to 24
(on- and off-treatment) will be used, in which missing data will
be accounted for by the MMRM [28, 29]. The model includes
fixed categorical effects of treatment group, randomization strata
time point, treatment-by-time point and strata-by-time point
interaction as well as the continuous fixed covariates of baseline
LDL-C value and baseline value-by-time point interaction.
Secondary Analysis A hierarchical procedure will be used to
control type I error and handle multiple secondary endpoints
analyses. If the primary endpoint analysis (ITT) is significant
at 5 % alpha level, key secondary efficacy endpoints will be
tested sequentially in the order given in Table 2. In particular,
LDL-C reduction at Week 24 will be analyzed on-treatment in
the modified ITT population (i.e. patients with at least one
baseline and at least one calculated LDL-C value available on-
treatment between Week 4 and 24) if the primary analysis is
significant in the ITT population.
Continuous secondary endpoints, except Lp(a) and triglyc-
erides, will be analyzed using the same MMRM model as for
the primary endpoint. Lp(a) and triglycerides (which have a
non-Gaussian distribution), and the binary secondary end-
points (proportion of patients with LDL-C <70 mg/dL and
<100 mg/dL) will be analyzed using a multiple imputation
approach for handling of missing values followed by robust
regression [30] (for Lp(a) and triglycerides) or logistic regres-
sion (for binary endpoints).
Safety Analysis
AEs (including adjudicated CV events), laboratory parame-
ters, and vital signs will be reported descriptively, based on the
safety population (all randomized patients who received at
least one dose or partial dose of study treatment). The safety
analysis will focus on the TEAE period defined as the time
from the first double-blind dose to the last double-blind dose
of the investigational product +70 days (10 weeks).
Patients entering the open-label extension study will be
followed up to their last visit in the double-blind treatment
period and their TEAE period will be truncated at this visit.
Timing of Analysis The analysis will be conducted in two
steps. The first step will be the main efficacy and safety
analyses conducted as soon as all patients have been random-
ized and have at least all their data up to Week 52 collected
and validated. In this step, the final analysis of the primary and
secondary efficacy endpoints up toWeek 52will be performed
as well as the safety analysis on all safety data collected and
validated at the time of the first analysis.
Of note, the results of the first analysis will not be used to
change the conduct of the ongoing study in any aspect. Since
the analyses of primary and key secondary efficacy endpoints
will be final at the time of first step analysis, the significance
level for the study remains at 0.05. The second step in the
analysis will be conducted at the end of the study and will
consist of the final analysis ofWeek 78 efficacy endpoints and
the final safety analysis.
Discussion
A recent consensus statement has been issued urging a world-
wide need to address the underdiagnosis and undertreatment
of patients with heFH [4]. The prevalence of heFH comes
from estimates based on a theoretical frequency of 1/500 in the
general population, and recent numbers indicate that approx-
imately 689,900 individuals in the USA and Canada, 527,500
in Europe and 100,000 in South Africa have heFH [4].
Furthermore, some studies have indicated the prevalence can
range from 1/500 to 1/200, and based on extrapolations, it is
estimated that there are between 14 and 34 million individuals
with heFH worldwide [4]. In many countries, however, less
than 1 % of patients are diagnosed [4].
A diagnosis of heFH is typically made based on family
history, clinical history of CHD, physical examination for
xanthomas and corneal arcus, and very high levels of LDL-
C; it can also be made by genotyping [31]. However, despite
the increased understanding of genetic causes and direct de-
tection of mutations in the LDLR, APOB, PCSK9 and
LDLRAP genes, the vast majority of diagnoses still rely on
the more historical clinical criteria.
Although it has been demonstrated that statin therapy, with
or without other LLT, can reduce the risk of CHD in patients
with heFH [5–7], many patients with heFH still do not achieve
desired LDL-C levels [8–12, 22, 24, 32, 33] and more
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intensive treatment options for these high-risk patients are
required [4]. To help address this unmet need, new approaches
to lowering LDL-C, including monoclonal antibodies to
PCSK9 administered as subcutaneous injection, are currently
in development.
In evaluating the efficacy and safety of such antibodies to
PCSK9, a Phase 2, randomized controlled trial of alirocumab
conducted in patients with heFH and LDL-C levels >100 mg/
dL despite their current LLT of a statin, with or without
ezetimibe, showed that alirocumab was well tolerated and
also showed statistically significant reductions in LDL-C
levels at all doses of alirocumab compared with placebo
[24]. With the large reductions in LDL-C, up to 94 % of
patients achieved LDL-C levels <100 mg/dL and up to 81 %
achieved levels <70 mg/dL [24]. In another Phase 2, random-
ized controlled trial with evolocumab in heFH patients with
LDL-C levels >100 mg/dL despite receiving statin therapy,
with or without ezetimibe, findings showed substantial
reductions in LDL-C levels with evolocumab compared
with placebo [22].
The ODYSSEY FH studies are Phase 3 studies aiming to
further demonstrate the potential of alirocumab as an effective
therapeutic option for patients with this severe disorder. The
uptitration dosing strategy in FH I and FH II allows for
flexibility and individualized therapy based on the degree of
LDL-C reduction required to achieve the desired treatment
response. In HIGH FH, where patients entered the study with
LDL-C values ≥160 mg/dL despite receiving a maximally
tolerated statin dose, with or without ezetimibe, it was deemed
appropriate to initiate the higher, 150 mg Q2W, dose of
alirocumab. In addition, the option for patients to enter an
open-label extension study at the end of the double-blind
treatment period will allow for further assessment of the
efficacy and safety of alirocumab.
Acknowledgments The ODYSSEY FH studies were supported by
Sanofi and Regeneron Pharmaceuticals, Inc. The design and conduct of
the study, as well as analysis of the study data and opinions, conclusions,
and interpretation of the data, are the responsibility of the authors.
Medical writing support in the preparation of this publication was pro-
vided by Betty Thompson, Ph.D., of Prime Medica and sponsored by
Sanofi and Regeneron Pharmaceuticals, Inc. The authors were responsi-
ble for all content and editorial decisions and received no honoraria
related to the development/presentation of this publication.
Investigators FH I
Canada: Robert DuFour (Montreal, Quebec); Jean Bergeron (Sainte-
Foy, Quebec); Daniel Gaudet (Montreal, Quebec); Patrice Perron
(Sherbrooke, Quebec); Lawrence Leiter (Toronto, Ontario)
United States: Thomas Barringer (Charlotte, NC); Robert Fishberg
(Summit, NJ); Henry Ginsberg (New York, NY); Anne Goldberg (St
Louis,MO); John Guyton (Durham,NC); LindaHemphill (Boston,MA);
John Homan (Newport Beach, CA); Patrick Moriarty (Kansas City, KS);
Galal Salem (Bell Gardens, CA); Erich Schramm (Ponte Vedra, FL);
Prediman Shah (Los Angeles, CA); Chad Wadell (Mission Viejo, CA);
Ralph Wade (Bountiful, UT); Jonathan Purnell (Portland, OR); Robert
Weiss (Lewiston, ME); Marina Cuchel (Philadelphia, PA);
Emanuel Shaoulian (Newport Beach, CA); Robert Greenfield
(Fountain Valley, CA); Traci Turner (Cincinnati, OH); Alan
Brown (Oakbrook Terrace, IL); Jeffrey Geohas (Evanston, IL);
Frederick Dunn (Dallas, TX)
Austria: Rudolf Prager (Wien); Hermann Toplak (Graz); Evelyn
Fliesser-Goerzer (St Stefan)
Czech Republic: Marketa Galovcova (Praha 4); Josef Machacek
(Zlin); Jan Zeman (Praha 8); Stanislav Zemek (Uherské Hradiště)
Denmark: Erik Schmidt (Aalborg); Kristian Thomsen (Esbjerg);
Pernille Correll (Roskilde)
France: Eric Bruckert (Paris); Michel Krempf (Saint-Herblain);
Michel Farnier (Dijon); Gerald Luc (Lille)
Israel: Hofit Cohen (Tel-Hashomer); Dov Gavish (Holon); Osamah
Hussein (Safed); Daniel Schurr (Jerusalem)
Netherlands: S.H.J. Donders (Groningen); G. Kees Hovingh
(Amsterdam); P. Viergever (Den Helder); H.H. Vincent (Nieuwegein);
A. Loualidi (Delfzijl); S.C.C. Hartong (Sliedrecht); A.A. Kroon
(Maastricht); Jacqueline De Graaf (Nijmegen)
Norway: Anders Hovland (Bodo)
Russia: Evgenia Akatova (Moscow); Vadim Arkhipovsky
(Arkhangelsk); Elena Demchenko (St. Petersburg); Victor Gurevich (St.
Petersburg); Gadel Kamalov (Kazan); Anastasia Lebedeva (Moscow);
Viacheslav Marasaev (Yaroslavl); Svetlana Mustafina (Novosibirsk);
Andrey Susekov (Moscow)
Spain: Luis Alvarez-Sala (Madrid); Fernando Civeira (Zaragoza-
Aragon); Jose Luis Diaz Diaz (La Coruna- Galicia); Nuria Plana Gil
(Reus-Tarragona); Rodrigo Alonso (Madrid); Francisco Fuentes
Jimenez (Cordoba); Xavier Pinto Sala (Barcelona); Emilio Ros
(Barcelona); Jose Luis Mostaza Prieto (Madrid)
Sweden: A. Ohlsson-Önerud (Stockholm); Stefano Romeo
(Goteborg)
United Kingdom: Graham Bayly (Bristol); Jacob George (Dundee);
Basil Issa (Manchester); Gordon Ferns (Brighton)
SouthAfrica: F.C.J. Bester (Bloemfontein); Dirk Blom (Cape Town);
Lesley Burgess (Cape Town); Shaunagh Emanuel (Cape Town); Nyda
Fourie (Bloemfontein); Maria Pretorius (Cape Town); Frederick Raal
(Johannesburg); Prashilla Soma (Pretoria); Shirley Middlemost
(Western Cape)
FH II
Czech Republic: Richard Ceska (Praha 2); Vladmir Blaha (Hradec
Kralove); Jana Cepova (Praha 5); Hana Halamkova (Vyskov); Lucie
Solcova (Trutnov); Jana Jirouskova (Praha 8).
Netherlands: G. Kees Hovingh (Amsterdam); Stan Peter Janssen
(Utrecht); H.W.O. Roeters van Lennep (Goes); Roel P.T. Troquay
(Venlo); B.E. Groenemeijer (Apeldoorn); J.W. Hans Louwerenburg
(Enschede); Marcel A. van de Ree (Utrecht); Adriaan Kooy
(Hoogeveen); Suat Simsek (Alkmaar); Ben P.M. Imholz (Waalwijk);
P.W. Kamphuisen (Groningen); Castro Cabezas (Rotterdam); Dick
Basart (Hoorn).
Norway: Gisle Langslet (Oslo); Eli Heggen (Oslo).
UK: See Kwok (Manchester); D.D.R. Nair (London); Alan Rees
(Cardiff); R.D.G. Neely (Newcastle upon Tyne); Elizabeth Hughes
(West Bromwich).
HIGH FH
Canada: Patrice Perron (Sherbrooke, Quebec); Jean Bergeron
(Sainte-Foy, Quebec)
United States: Henry Ginsberg (New York, NY); John Guyton
(Durham, NC); John Homan (Newport Beach, CA); Marina Cuchel
(Philadelphia, PA); Rashmi Schramm (Ponte Vedra, FL); Robert
Greenfield (Fountain Valley, CA); Traci Turner (Cincinnati, OH); Lisa
Martin (Washington, DC); Frederick Dunn (Dallas, TX); Robert DeLuca
(Miami, FL); Galal Salem (Bell Gardens, CA)
Netherlands: E.S.G. Stroes (Amsterdam); S.H.J. Donders
(Groningen); Marcel A. van de Ree (Utrecht); J.P.R. Herrman
(Amsterdam); M.V. Huisman (Leiden)
Cardiovasc Drugs Ther (2014) 28:281–289 287
Russia: Elena Demchenko (St. Petersburg); Anastasia Lebedeva
(Moscow); Gadel Kamalov (Kazan); Vadim Arkhipovsky
(Arkhangelsk); Viacheslav Marasaev (Yaroslavl); Evgenia Akatova
(Moscow); Victor Gurevich (St. Petersburg); Andrey Susekov (Moscow)
South Africa: F.C.J. Bester (Bloemfontein); Frederick Raal
(Johannesburg); Shirley Middlemost (Western Cape); Nyda Fourie
(Bloemfontein); Maria Pretorius (Cape Town)
Steering Committee Chairman: Henry Ginsberg, MD (Irving Institute
for Clinical and Translational Research, Columbia University New York,
NY USA). Members: Jennifer G. Robinson, MD, MPH (The University
of Iowa, Iowa City, IA USA); Daniel J. Rader, MD (Institute for
Translational Medicine and Therapeutics, University of Pennsylvania
School of Medicine Philadelphia, PA USA); Christopher P. Cannon,
MD (Senior Investigator, TIMI Study Group; Professor of Medicine,
Harvard Medical School Cardiovascular Division, Brigham and
Women’s Hospital, Boston, MA USA); Helen Colhoun, MD, MFPHM
(Clinical Centre, University of Dundee, Ninewells Hospital & Medical
School, Dundee, UK); John J.P. Kastelein, MD (Academic Medical
Center University of Amsterdam, Amsterdam, The Netherlands);
Michel Farnier, MD (Point Médical, Département d’Endocrinologie et
de Lipidologie, Dijon, France).
Data Monitoring Committee DMC Chairman: Anders Olsson, MD
(Bromma, Sweden). Members: David Waters, MD (Division of
Cardiology, San Francisco General Hospital, San Francisco, CA USA);
Dominique Larrey, MD (Hôpital Saint-Eloi Service d’hépato-gastro-
entérologie, Montpellier, France); Robert S Rosenson, MD (Director,
Cardiometabolic Disorders, Mount Sinai Heart; Professor of Medicine,
Mount Sinai School of Medicine, New York, NY USA); Peter A.
Patriarca, MD (Biologics Consulting Group, Inc., Alexandria, VA
USA); Geert Molenberghs, Biostatistician (Center for Statistics
(CenStat) Universiteit Hasselt Agoralaan 1, Diepenbeek, Belgium).
Clinical Events Committee (Reviewers), Duke Clinical Research
Institute, Durham, NC USA Pierluigi Tricoci, CEC Principal
Investigator, Cardiology; Kenneth W Mahaffey, CEC Director,
Cardiology; Renato D Lopes, Cardiology; Bimal R Shah, Cardiology;
Rajendra H Metha, Cardiology; Matthew T Roe, Cardiology; Zubin
Eapen, Cardiology; Luciana Armaganijan, Cardiology; Adriana
Bertolami, Cardiology; Sergio Leonardi, Cardiology; Bradley J. Kolls,
Neurology; J. Dedrick Jordan, Neurology; Grégory Ducrocq, Cardiology;
Etienne Puymirat, Cardiology; Robin Mathews, Cardiology.
Disclosures Dr. Kastelein is a consultant to and receives honoraria
from: Regeneron, Sanofi, Eli Lilly, Pfizer, Amgen, Isis, Genzyme,
Aegerion and Esperion. He is a recipient of the Lifetime Achievement
Award of the Dutch Heart Foundation (2010T082).
Dr. Robinson is employed by a University that has received research
funds from Amarin, Amgen, AstraZeneca, Daiichi-Sankyo, Esperion,
Genetech/Hoffman La Roche, Glaxo-Smith Kline, Merck, Regeneron/
Sanofi, Zinfandel/Takeda and is a consultant for Amgen, Pfizer, Sanofi
and Regeneron.
Dr. Farnier reports having received grants, consulting fees and/or
honoraria and delivering lectures for Abbott, Amgen, Boehringer-
Ingelheim, Genzyme, Kowa, Merck and Co, Novartis, Pfizer,
Recordati, Roche, Sanofi-Aventis, and SMB.
Dr. Langslet has received advisory board fees from Sanofi-Aventis
and Janssen Pharmaceuticals.
Dr. Krempf has received grants, consulting fees and/or honoraria and
delivering lectures for Abbott, Amgen, Astra Zeneca, BMS, Merck and
Co, Novartis, Pfizer, Roche, Sanofi-Aventis.
Christelle Lorenzato and Marie T. Baccara-Dinet are employees of
Sanofi.
Daniel A. Gipe is an employee of Regeneron.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Goldstein JL, Hobbs HH, BrownMS. Familial hypercholesterolemia.
In: Scriver CR, Sly WS, Childs B, et al., editors. The metabolic
and molecular bases of inherited disease. 8th ed. New York:
McGraw-Hill; 2001. p. 2863–913.
2. NICE clinical guidelines 71. Identification and management of fa-
milial hypercholesterolemia. Issue date: August 2008. Available
from: URL: http://www.nice.org.uk/nicemedia/live/12048/41697/
41697.pdf. Accessed Mar 2013.
3. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in
116 kindred with familial type II hyperlipoproteinemia. Circulation.
1974;49:476–88.
4. Nordestgaard BG, Chapman MJ, Humphries SE, for the European
Atherosclerosis Society Consensus Panel, et al. Familial hypercho-
lesterolaemia is underdiagnosed and undertreated in the general
population: guidance for clinicians to prevent coronary heart disease:
Consensus Statement of the European Atherosclerosis Society. Eur
Heart J. 2013;34:3478–90a.
5. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer,
and coronary mortality in statin-treated patients with heterozygous
familial hypercholesterolaemia: a prospective registry study. Eur
Heart J. 2008;29:2625–33.
6. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treat-
ment on the clinical fate of heterozygous familial hypercholesteremia. J
Atheroscler Thromb. 2010;17:667–74.
7. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of
statins in familial hypercholesterolaemia: a long term cohort study.
BMJ. 2008;337:a2423.
8. Huijgen R, Kindt I, Verhoeven S, et al. Two years after molecular
diagnosis of familial hypercholesterolemia: majority on cholesterol-
lowering treatment but a minority reaches treatment goal. PLoS
ONE. 2010;5:e9220.
9. Gitt AK, Jünger C, Smolka W, Bestehorn K. Prevalence and overlap
of different lipidabnormalities in statin-treated patients at high car-
diovascular risk in clinical practice in Germany. Clin Res Cardiol.
2010;99:723–33.
10. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholester-
olemia: screening, diagnosis and management of pediatric and adult
patients: clinical guidance from the National Lipid Association
Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol.
2011;5(3, Supplement 1):S1–8.
11. PijlmanAH,Huijgen R,Verhagen SN, et al. Evaluation of cholesterol
lowering treatments of patients with familial hypercholesterolemia: a
large cross-sectional study in The Netherlands. Atherosclerosis.
2010;209:189–94.
12. Stein EA, Strutt K, Southworth H, HeFH study group, et al. Comparison
of rosuvastatin versus atorvastatin in patients with heterozygous familial
hypercholesterolemia. Am J Cardiol. 2003;92:1287–93.
13. Stone N, Robinson J, Lichtenstein A, et al. ACC/AHA guideline on
the treatment of blood cholesterol to reduce atherosclerotic cardio-
vascular risk in adults. Circulation. 2013.
14. Abifadel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause
autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:
154–6.
15. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the
number of LDL receptors in hepatocytes and in livers of parabiotic
mice. J Clin Invest. 2006;116:2995–3005.
288 Cardiovasc Drugs Ther (2014) 28:281–289
16. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9
accelerates the degradation of the LDLR in a post-endoplasmic
reticulum compartment. Proc Natl Acad Sci U S A. 2005;102:
2069–74.
17. Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function
PCSK9 variant is associated with low plasma LDL cholesterol in a
French-Canadian family and with impaired processing and secretion
in cell culture. Clin Chem. 2011;57:1415–23.
18. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin
causes a rapid sustained increase in human serum PCSK9 and dis-
rupts its correlation with LDL cholesterol. J Lipid Res. 2010;51:
2714–21.
19. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolera-
bility of a monoclonal antibody to proprotein convertase subtilisin/
kexin type 9 in combination with a statin in patients with hypercho-
lesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-
controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007–17.
20. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of
a monoclonal antibody to proprotein convertase subtilisin/kexin type
9 as monotherapy in patients with hypercholesterolaemia
(MENDEL): a randomised, double-blind, placebo-controlled, phase
2 study. Lancet. 2012;380:1995–2006.
21. McKenney JM, KorenMJ, Kereiakes DJ, et al. Safety and efficacy of
a monoclonal antibody to proprotein convertase subtilisin/kexin type
9 serine protease, SAR236553/RENGN727, in patients with primary
hypercholesterolemia receiving ongoing stable atorvastatin therapy. J
Am Coll Cardiol. 2012;59:2344–53.
22. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein
cholesterol-lowering effects of AMG-145, a monoclonal antibody
to proprotein convertase subtilisin/kexin type 9 serine protease in
patients with heterozygous familial hypercholesterolemia: the reduc-
tion in LDL-C with PCSK9 inhibition in heterozygous familial
hypercholesterolemia disorder (RUTHERFORD) randomized trial.
Circulation. 2012;126:2408–17.
23. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or
without an antibody to PCSK9 in primary hypercholesterolemia. N
Engl J Med. 2012;367:1891–900.
24. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to
PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cho-
lesterol in patients with heterozygous familial hypercholesterolaemia on
stable statin dose with or without ezetimibe therapy: a phase 2
randomised controlled trial. Lancet. 2012;380:29–36.
25. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal
antibody to PCSK9 on low-density lipoprotein cholesterol levels in
statin-intolerant patients. The GAUSS randomized trial. JAMA.
2012;308:1545–54.
26. Scientific Steering Committee on behalf of the Simon Register
Group. Risk of fatal coronary heart disease in familial hypercholes-
terolaemia. BMJ. 1991;303:893–6.
27. World Health Organization. Familial Hypercholesterolaemia (FH):
report of a second WHO consultation. Geneva: World Health
Organization; 1999.
28. Siddiqui O, Hung HM, O’Neill R. MMRM vs. LOCF: a comprehen-
sive comparison based on simulation study and 25 NDA datasets. J
Biopharm Stat. 2009;19:227–46.
29. National Research Council. The prevention and treatment of missing
data in clinical trials. Panel on Handling Missing Data in Clinical
Trials. Committee on National Statistics, Division of Behavioral and
Social Sciences and Education. Washington, DC: The National
Academies Press; 2010.
30. Mehrotra DV, Li X, Liu J, Lu K. Analysis of longitudinal clinical
trials with missing data using multiple imputation in conjunction with
robust regression. Biometrics. 2012;68:1250–9.
31. Civeira F. Guidelines for the diagnosis and management of hetero-
zygous familial hypercholesterolemia. Atherosclerosis. 2004;173:
55–68.
32. Stein E, Stender S, Mata P, Ezetimibe Study Group, et al. Achieving
lipoprotein goals in patients at high risk with severe hypercholester-
olemia: efficacy and safety of ezetimibe co-administered with
atorvastatin. Am Heart J. 2004;148:447–55.
33. Stein EA, Ose L, Retterstol K, et al. Further reduction of low-density
lipoprotein cholesterol and C-reactive protein with the addition of
ezetimibe to maximum-dose rosuvastatin in patients with severe
hypercholesterolemia. J Clin Lipidol. 2007;1:280–6.
Cardiovasc Drugs Ther (2014) 28:281–289 289
